Skip to Content
Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 08/26/21

Bladder SPOREs

Bladder cancer has an estimated 83,370* new cases and 17,200 deaths in 2021. The percent of patients surviving for 5 years is 77%. The incidence rate is about 4 times higher in men than in women and 2 times higher in White men than in Black men. The Memorial Sloan Kettering Cancer Center Bladder SPORE was funded in 2018 with goals to 1- Develop predictive biomarkers based on patientsí response or resistance to chemotherapy and immunotherapy, 2- Access a large set of familial patient samples (>1000) and use genome sequencing technologies to identify novel inherited susceptibility genes, 3- Understand why patients treated with immunotherapy (anti PD-L1) have limited response and find predictive markers of response and resistance to guide combination therapies, and 4- Explore immunologic predictors of BCG immunotherapy.